Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow’s leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic’s many resources and see jobs available for medical professionals. Get updates.
Give to Mayo ClinicHelp set a new world standard in care for people everywhere. Give now.
The GALAD model is a statistical model for estimating the likelihood of hepatocellular carcinoma (HCC) in patients with chronic liver disease.
This calculator is intended for use by health care providers. The results of this tool should never be used alone to determine a patient's medical treatment. This tool is a statistical model and is not a substitute for an individual treatment plan developed by a doctor with personal knowledge of a specific patient. Other important factors that must be considered include the patient's own medical history and the experience, knowledge and training of the doctor. Doctors should personally discuss these results with patients when presenting prognoses or treatment recommendations.
There is a problem with information submitted. Please review the fields highlighted below and resubmit.
Please select sex
Please enter an age (valid range: 10-100 years)
Please enter AFP range (valid range: 0.1-10,000,000 ng/mL)
Please enter AFP-L3 range (valid range: 0-100%)
Please enter DCP range (valid range: 0.1-75,000 ng/mL)
recommendation text goes here.
This probability estimate is dependent on the prevalence of the disease (HCC) within the specific population.
The GALAD model was developed in a cohort where 49% of the population had HCC.
According to Mayo Clinic internal data, a GALAD score of 1.17 is a cutoff providing 98% specificity and 63% sensitivity.
The GALAD model was developed using data from 670 patients (331 with HCC and 339 with chronic liver disease) from a single UK center and has been validated in independent cohorts of 6834 patients (2430 with HCC and 4404 with chronic liver disease) recruited from Germany, Japan, and Hong Kong.
Performance of the GALAD score varies by etiology of HCC and therefore differs in different regions of the world.
Mayo Clinic is a not-for-profit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.